Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review

• Published in: Biochimica et biophysica acta. General subjects Vol. 1865; no. 1; p. 129736
• Main Authors: Tangella, Lokeswari P., Clark, Michael E., Gray, Elin S.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2021
• Subjects: Acquired resistance; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; cancer therapy; combination drug therapy; disease resistance; drug resistance; Drug Resistance, Neoplasm; enzyme inhibition; genetic heterogeneity; genetic resistance; Humans; Intrinsic resistance; MAP Kinase Signaling System - drug effects; melanoma; Melanoma - drug therapy; Melanoma - genetics; Melanoma - metabolism; Metabolic reprogramming; mitogen-activated protein kinase; Molecular Targeted Therapy; mutants; Mutation - drug effects; neoplasm cells; non-specific serine/threonine protein kinase; phenotypic plasticity; precision medicine; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Proto-Oncogene Proteins B-raf - genetics; Proto-Oncogene Proteins B-raf - metabolism; resistance mechanisms; survival rate; Targeted therapy; Tumour adaptations; Tumour plasticity; Tumour adaptations; Intrinsic resistance; Acquired resistance; Metabolic reprogramming; Targeted therapy; Tumour plasticity
• ISSN: 0304-4165; 1872-8006; 1872-8006
• DOI: 10.1016/j.bbagen.2020.129736

The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have improved survival rates in a significant proportion of patients. Nonetheless, the emergence of resistance to treatment remains inevitable in most patients. Here, we review known and emerging molecular mechanisms t...